- 专利标题： Inhibition of crystal growth of roflumilast
-
申请号： US17102056申请日： 2020-11-23
-
公开(公告)号： US11793796B2公开(公告)日： 2023-10-24
- 发明人: David W. Osborne
- 申请人： ARCUTIS, INC.
- 申请人地址： US CA Westlake Village
- 专利权人： Arcutis Biotherapeutics, Inc.
- 当前专利权人： Arcutis Biotherapeutics, Inc.
- 当前专利权人地址： US CA Westlake Village
- 代理机构： Rothwell, Figg, Ernst & Manbeck, P.C.
- 分案原申请号： US15616409 2017.06.07
- 主分类号： A61K31/44
- IPC分类号： A61K31/44 ; A61K9/00 ; A61K47/10 ; A61K9/06 ; A61K9/14 ; A61K45/06 ; C09K15/06
摘要：
Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.
公开/授权文献
- US20210244718A1 INHIBITION OF CRYSTAL GROWTH OF ROFLUMILAST 公开/授权日：2021-08-12
信息查询
